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Abstract. Fosmidomycin is the first representative of a new class of antimalarial drugs acting 
through inhibition of 1-deoxy-D-xylulose 5-phosphate (DOXP) reductoisomerase (DXR), an 
essential enzyme in the non-mevalonate pathway for the synthesis of isoprenoids. This work 
describes a divergent strategy for the synthesis of a series of -aryl substituted fosmidomycin 
analogues, featuring a palladium-catalyzed Stille coupling as the key step. An -(4-
cyanophenyl)fosmidomycin analogue emerged as the most potent analogue in the present 
series. Its antimalarial activity clearly surpasses that of the reference compound 
fosmidomycin.  
 
Introduction. According to the WHO, malaria still causes 1.5 to 2 million casualties in Africa 
alone, amongst which mainly children. One of the major reasons for the spreading of the 
disease is the growing resistance of Plasmodium falciparum, the parasite species responsible 
for the most of the diagnosed cases, towards almost every antimalarial drug currently 
available. Therefore, the discovery of novel inhibitors targeting new biochemical pathways is 
of high priority. 
In 1980, Okuhura and colleagues reported the first isolation of fosmidomycin (1), a 
structurally simple antibiotic from Streptomyces lavendulae.1,2 
In 1998, 1-deoxy-D-xylulose 5-phosphate (DOXP) reductoisomerase, an enzyme involved in 
the 2C-methyl-D-erythritol 4-phosphate (MEP) pathway for the biosynthesis of isoprenoids 
and absent in humans, was identified as the molecular target for fosmidomycin.3,4 
Fosmidomycin was found to be a potent inhibitor of DOXP reductoisomerase (DXR) of P. 
falciparum.4 FR900098 (2), the acetyl congener of fosmidomycin, was shown to be 
approximately twice as active against P. falciparum in vitro, as well as in a P. vinckei mouse 
model.4 
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Due to this promising antimalarial activity, fosmidomycin received considerable attention, 
and recent clinical trials conducted in Gabon and Thailand confirmed the potential of 
fosmidomycin as an antimalarial drug.5,6 
These important discoveries stimulated research on the chemical synthesis of fosmidomycin 
analogues. Structural changes of fosmidomycin and FR900098 could provide essential 
information on the structure-activity relationship and produce improved leads for the 
treatment of malaria. Mostly, attention was focused on the modification of the phosphonate 
and hydroxamate moieties, yielding, on one hand, various phosphonate prodrugs aimed to 
enhance the oral bioavailability, and on the other hand, modifications of the retrohydroxamate 
moiety into a hydroxamic acid, amongst others.7-11 Structural variations of the three-carbon 
spacer, however, are scarce. Our group recently reported the synthesis of conformationally 
restricted analogues in which the carbon spacer was part of a cyclopropyl or cyclopentyl 
ring.12,13  
Up to date, the most promising modifications of the carbon spacer consist of the introduction 
of an aryl substituent in α-position of fosmidomycin or FR900098.14 Recently, we identified 
the α-3,4-dichlorophenyl substituted fosmidomycin analogue which exhibits a 12 times 
stronger in vitro antimalarial activity (Dd2 and 3D7 strains of P. falciparum) compared to 
fosmidomycin. Lately, Kurz and coworkers evaluated the effect of α-substituents on 
pivaloyloxymethyl ester prodrugs of fosmidomycin and FR900098.15,16 The α-methyl and 
phenyl analogues proved almost equipotent and the 3,4-difluorophenyl analogue slightly 
better than the FR900098 prodrug in inhibiting growth of a 3D7 P. falciparum strain.15 
Incorporation of an arylmethyl moiety in -position generally resulted in a marked decrease 
in activity.16 Unfortunately, the strategy used to synthesize the α-aryl substituted analogues 
involved a de novo synthetic approach, which permitted only to synthesize a limited number 
of examples. To further explore the structure-activity relationship of this class, a strategy 
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involving the incorporation of the aryl moiety at a later stage in the synthesis would be 
desirable. 
Results and discussion. Here we describe a highly efficient divergent synthesis of a series of 
-aryl substituted fosmidomycin analogues 3-5, involving the α-tributylstannyl derivative 6 as 
a key intermediate (Chart 1). The vinylic tributyltin functionality of this intermediate was 
subjected to a palladium(0)-catalyzed Stille coupling with a variety of commercially available 
or readily synthesized aryl iodides.  
Chart 1. Target fosmidomycin and FR900098 analogues and retrosynthetic plan involving 
key intermediate 6.  
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Scheme 1. Synthesis of -aryl substituted N-acetyl fosmidomycin analogues. 
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aReagents and conditions: (a) (i) n-BuLi, THF, –78 °C; (ii) (EtO)2P(O)Cl; HOAc; (iii) p-
TsOH, MeOH, rt; (b) NsNHOBn, DEAD, PPh3, THF, rt; (c) Bu3SnH, Pd(PPh3)4, THF, 0 °C; 
(d) Ar-I, Pd2dba3.CHCl3, (2-furyl)3P, CuI, NMP, rt; (e) (i) PhSH, K2CO3, MeCN, DMSO, 70 
°C; (ii) Ac2O; (f) H2, Pd/C, Na2CO3, THF, rt; (g) BCl3, CH2Cl2, –50 °C; (h) TMSBr, MeCN, 
rt; C-18 RP-HPLC; (i) TMSBr, MeCN, rt; NH4OH(aq); CF11-cellulose chromatography 
 
The synthesis of said key intermediate 6 started with the conversion of the THP-protected 
propargyl alcohol 7 to diethyl (3-hydroxypropynyl)-phosphonate (8) in a yield of 64%.17 
Subsequently, the hydroxyl group of compound 8 was displaced by a protected 
hydroxylamino moiety under Mitsunobu conditions. Nucleophilic substitution of the 
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corresponding tosylate proved unsuccessful, due to 1,4-addition of the nucleophile to the 
alkynyl phosphonate. Although extensive examples of successful Mitsunobu couplings are 
found in literature using carbamoyl-protected hydroxylamines,18,19 introduction of a protected 
hydroxylamine moiety only succeeded using N-benzyloxy-2-nitrobenzenesulfonamide.20 
Indeed, the 2-nitrobenzenesulfonamide (or nosyl/Ns) moiety effectively enhances the acidity 
of the proton on the nitrogen, whereas in the case of the Boc-protected hydroxylamine, its 
acidity is not sufficient for reaction to occur. 
Subsequently, a palladium(0)-catalyzed addition of Bu3SnH to the triple bond of compound 9 
afforded 1-tributylstannyl-propenylphosphonate 6 as a single isomer in an excellent yield of 
90%. The E-geometry was assigned based on the 3JPH coupling constant in the 1H NMR 
spectrum (62.7 Hz), which is in accordance with the large coupling constant typically found 
for a vinylic proton trans to a phosphonate.21 Optimization of the Stille coupling on the 
organotin derivative 6 afforded compounds 10f-g in good yields using a combination of 
Pd2dba3.CHCl3, tri(2-furyl)phosphine and anhydrous CuI in NMP.22 Under these conditions, 
apparently no homo-coupling of 6 was detected and the geometry of the double bond was 
retained. Removal of the nosyl group of 10f-g with thiophenol and K2CO3 followed by in situ 
acylation, however, provided compounds 12f-g in rather disappointing yields.23 Apparently, 
the specific conditions used for the deprotection of the nosyl group are not fully compatible 
with the (substituents on the) aryl moiety. Therefore, we investigated if steps d and e could be 
interchanged. An additional advantage of moving the nosyl deprotection step forward in the 
synthesis is that it enhances the divergent character of the sequence. Thus, compound 6 was 
first deprotected and in situ acylated in excellent yield. Subsequent Stille coupling on the 
organotin compound 11 using the above-mentioned conditions led to compounds 12a-h in 
good to excellent yields. The method proves highly compatible with a wide range of diverse 
functionalities, including hetereoaromatic rings (12g-h). The current methodology requires 
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the use of aryl iodides, since aryl bromides only induced homo-coupling of 6. 4-
Iodobenzamide, required for preparing 12c, is not commercially available, but was readily 
synthesized from 4-iodobenzonitrile.  
Reduction of the ,-double bond, combined with removal of the benzyl protecting group on 
compounds 12a-f, was accomplished using palladium on carbon (10% Pd/C) and anhydrous 
Na2CO3 in dry THF under slightly positive atmospheric H2-pressure. Reaction times varied 
from 3 to 14 h to afford compounds 13a-d,i-j in moderate to excellent yields. During this 
hydrogenation step little or no deoxygenation of the hydroxamic acid was observed, in 
contrast to previously reported N-O bond cleavage during catalytic hydrogenation.13 In case 
of the conversion of compound 12b, short reaction times were necessary to prevent reduction 
of the nitrile substituent on the phenyl ring. Reduction of the nitro group in compounds 12e-f 
was unavoidable, resulting in amino-compounds 13i-j. Furthermore, reduction of the 2-thienyl 
(12g) and 3-thienyl (12h) compounds was successfully accomplished only when using more 
than 1 equivalent of Pd/C. Presumably the sulphur atom in the thiophene ring is poisoning the 
catalyst. Remarkably, simultaneous removal of the benzyl protecting group was not observed 
for these thienyl compounds, yielding the O-protected saturated compounds 14g-h. 
Subsequent deprotection of the benzyl protecting group with BCl3 afforded compounds 13g-h 
in good to excellent yields. Finally, the phosphonate ester groups of the -aryl FR900098 
analogues 13a-d,g-j were cleaved with TMSBr. Two different methods for purification of the 
final phosphonic acid compounds were used. The first, more traditional method involves 
removal of the solvent, addition of water, lyophilisation of the solution and purification of the 
solids via reversed phase chromatography. This method was used for the purification of 
compounds 3a,d,i-j but suffers from some serious drawbacks. First, the resulting phosphonic 
acids are only sparingly soluble in water or MeOH. Second, the C-18 reversed phase column 
used for purification strongly absorbs the phosphonic acids 3a,d,i-j, resulting in a low 
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recovery. This pronounced retention was not observed for more polar fosmidomycin 
analogues,12 hence it could be correlated to the affinity of the aryl moiety for the stationary 
phase of the HPLC column. Third, the C-18 HPLC column used only allows for a maximum 
loading of 30 mg of crude material each time, which is very time consuming for the 
purification of larger amounts of crude analogues. Therefore, a second methodology was 
investigated, comprising removal of the solvent, addition of water followed by dropwise 
addition of a 5% aqueous NH4OH solution until pH 8-9 was reached. Subsequently, the 
solution was lyophilised and the product was purified via column chromatography using 
Whatman CF11-cellulose.24 LC-MS analysis of the crude solids before chromatographic 
purification only showed NH4Br (resulting from a reaction of TMSBr with NH4OH) as a 
contaminant. The CF11-cellulose proved very effective in separating this contaminant from 
compounds 4b-c,g-h, which were isolated in high yields due to the low affinity for the 
stationary phase. Additionally the resulting bis-ammonium salts of the α-aryl phosphonates 
showed excellent solubility in water. 
Table 1. Inhibition of recombinant E. coli DXR by analogues 3, 4 and 5. 
Compound Ar R R’ IC50 (M) 
3a (4-CF3)Ph CH3 H 0.360 
4b (4-CN)Ph CH3 NH4 0.119 
4c (4-CONH2)Ph CH3 NH4 2.84 
3d (4-SO2NH2)Ph CH3 H 0.318 
4g 2-thienyl CH3 NH4 0.603 
4h 3-thienyl CH3 NH4 0.483 
3i (3-NH2)Ph CH3 H 1.45 
3j (4-NH2)Ph CH3 H 3.60 
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5 (4-CN)Ph H NH4 0.054 
Fosmidomycin (1) H H Na 0.056 
 
Because of the difficulties associated with the handling of P. falciparum DXR, we 
investigated the ability of the synthesized -aryl substituted FR900098 analogues 3a,d,i-j and 
4b-c,g-h to inhibit the highly homologous recombinant E. coli DXR. The conversion of 
DOXP to MEP by the enzyme was determined in an assay based on the NADPH dependency 
of the reaction.25 With respect to the slow, tight-binding properties of fosmidomycin and 
probably most of its derivatives the inhibitors were pre-incubated with the enzyme and 
NADPH before the reaction was started by the addition of DOXP.7,11,26 The results are 
summarized in Table 1. Compared to fosmidomycin, all synthesized analogues were found to 
be weaker inhibitors of E. coli DXR. Analysis of the order of DXR inhibitory potency (4b > 
3d > 3a > 3j) suggests that activity is Hammett -controlled (4-CN > 4-SO2NH2 > 4-CF3 > 
4-NH2). A similar trend was observed for the previously reported -phenyl substituted 
analogues.14 The weak inhibitory activity of the p-carbamoylphenyl analogue 4c of p-
carbamoylphenyl analogue 4c illustrates that the activity pattern is not exclusively Hammett 
-controlled. Also, incorporation of a 2- or 3-thienyl moiety in analogues (4g-h) negatively 
affects the inhibitory potency. 
Scheme 2. Synthesis of -aryl substituted fosmidomycin analogue 5. 
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aReagents and conditions: (a) (i) PhSH, K2CO3, MeCN, DMSO, 70 °C; (ii) 1,1'-
carbonyldiimidazole, HCOOH, 0 °C; (b) 4-iodobenzonitrile, Pd2dba3.CHCl3, (2-furyl)3P, CuI, 
NMP, rt; (c) H2, Pd/C, Na2CO3, THF, rt; (d) TMSBr, MeCN, rt; NH4OH(aq); CF11-cellulose 
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In previous studies, the -aryl substituted N-formyl-fosmidomycin analogues were generally 
superior DXR inhibitors as compared to their N-acetyl counterparts. Hence, we decided to 
synthesize the N-formyl congener of 4b, the most potent N-acetyl analogue in the present 
study. Towards the synthesis of 5 the above-mentioned strategy proved equally useful upon 
substituting in situ N-acetylation for N-formylation, using a mixture of HCOOH and 1,1’-
carbonyldiimidazole.13 (Scheme 2) 
In the enzyme assay (Table 1), compound 5 was approximately twofold more active than its 
acetyl congener 4b and equally active to fosmidomycin (1). More importantly, an in vitro 
antimalarial assay using intraerythrocytic stages of the P. falciparum D2d strain, proved that 
the activities of 4b (IC50 = 0.27 M) and 5 (IC50 = 0.27 M) surpass the activity of 
fosmidomycin (IC50 = 1.1 M) and even FR900098 (IC50 = 0.49 M) to inhibit parasite 
growth. 
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In conclusion, a highly accessible, divergent procedure for the preparation of α-aryl-
substituted fosmidomycin analogues 3, 4 and 5 with varying substituents was developed using 
a palladium(0)-catalyzed Stille coupling as a key step. The required organotin precursor 6 was 
prepared regio- and stereoselectively in four steps from protected propargyl alcohol 7, using a 
Pd(0)-catalyzed addition of tributyltin hydride as a key step. Two compounds (4b and 5), both 
possessing an -4-cyanophenyl group, exhibited a promising in vitro inhibitory activity for 
recombinant E. coli DXR comparable to that of fosmidomycin, and were even found to show 
a higher activity than fosmidomycin in an in vitro test against P. falciparum D2d strain. 
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Experimental section  
Diethyl 3-hydroxy-propynylphosphonate (8). A 1.6 M n-BuLi in hexanes (47.6 mL, 71.3 
mmol) was added dropwise to a stirred solution of tetrahydro-2-(2-propynyloxy)-2H-pyran (7, 
10 g, 71.3 mmol) in dry THF (100 mL) at –78 °C. After stirring for 30 min at the same 
temperature, a solution of diethylchlorophosphate (11.4 mL, 78.5 mmol) in dry THF (100 
mL) was added dropwise, after which the mixture was stirred for another 30 min at –78 °C. 
The reaction was quenched with saturated aqueous NH4Cl (100 mL) and the aqueous layer 
was extracted three times with Et2O (100 mL). The combined organic layers were dried on 
anhydrous MgSO4, filtered and the solvents were removed under reduced pressure. The 
residual oil was dissolved in MeOH (200 mL), p-TsOH (1.36 g, 7.13 mmol) was added and 
the reaction mixture was stirred overnight at rt. The solvent was removed under reduced 
pressure and the residual oil was purified via column chromatography (pentane/acetone: 3/2) 
yielding 8.75 g of a colorless oil (64%). Rf 0.30 (pentane/acetone: 3/2); 1H NMR (300.13 
MHz, CDCl3)  1.36 (6H, td, J = 7.1 and 0.6 Hz), 2.89 (1H, br s), 4.16 (4H, dq, J = 8.3 and 
7.0 Hz), 4.35 (2H, d, J = 3.7 Hz); 13C NMR (75.47 MHz, CDCl3)  16.0 (-CH3, 3JPC = 7.1 
Hz), 50.6 (-OCH2, 3JPC = 4.4 Hz), 63.5 (-OCH2, 2JPC = 5.5 Hz), 76.3 (C-P, 1JPC = 298.6 Hz), 
100.0 (C, 2JPC = 50.5 Hz); 31P NMR (121.50 MHz, CDCl3)  –6.7; ESMS m/z 193 
([M]+H+). 
Diethyl 3-[N-benzyloxy,N-(2-nitrobenzenesulfonyl)amino]-propynylphosphonate (9). 
To a stirred solution of alcohol 8 (6.58 g, 34.2 mmol), N-benzyloxy,N-(2-
nitrobenzene)sulfonamide (11.5 g, 37.3 mmol) and PPh3 (9.8 g, 37.3 mmol) in dry THF (180 
mL) a solution of DEAD (6.91 mL 85%, 37.3 mmol) in dry THF (90 mL) was added over 1 h 
at rt. The mixture was stirred for 20 h at room temperature. The solvent was removed under 
reduced pressure and the residual oil was purified via column chromatography (column 1: 
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pentane/CH2Cl2/acetone: 2/7/1, column 2: Et2O -> CH2Cl2/acetone: 1/1), yielding 11.7 g of a 
thick amber oil (71%). Rf 0.40 (pentane/CH2Cl2/acetone: 2/7/1); 1H NMR (300.13 MHz, 
CDCl3)  1.29 (6H, dt, J = 7.1 and 0.6 Hz), 3.99-4.06 (4H, m), 4.18 (2H, d, J = 3.9 Hz), 5.15 
(2H, s), 7.36-7.45 (5H, m), 7.56 (1H, dd, J = 7.8 and 1.2 Hz), 7.67 (1H, app dt, J = 7.7 and 1.3 
Hz), 7.78 (1H, app dt, J = 7.7 and 1.5 Hz), 8.04 (1H, dd, J = 7.9 and 1.3 Hz); 13C NMR (75.47 
MHz, CDCl3)  16.0 (CH3, 4JPC = 7.2 Hz), 43.1 (-NCH2, 3JPC = 5.5 Hz), 63.3 (-OCH2, 3JPC = 
5.5 Hz), 76.1 (C-P, 1JPC = 293.7 Hz), 80.6 (-OCH2), 91.9 (C, 2JPC = 51.0 Hz), 123.9 (=CH), 
126.O (=C), 128.7 (=CH), 129.2 (=CH), 129.9 (=CH), 131.4 (=CH), 133.2 (=CH), 134.2 
(=C), 135.6 (=CH), 149.5 (=C); 31P NMR (121.50 MHz, CDCl3)  8.2; Exact mass (ESI-MS): 
calculated for C20H23N2O8PS ([M]+H+) 483.09911; found 483.09654. 
Diethyl (E)-3-[N-(benzyloxy),N-(2-nitrobenzenesulfonyl)amino]-1-(tributylstannanyl)-
propenylphosphonate (6). To a cooled (0 °C) solution of 9 (10.4 g, 21.6 mmol) and 
Pd(PPh3)4 (474 mg, 0.430 mmol) in dry THF (100 mL) Bu3SnH (6.28 g, 21.6 mmol) was 
added over a period of 40 min. The reaction mixture was stirred at 0 °C for 1 h and then 
allowed to warm to room temperature in 2 h. The solvent was removed and the crude oil was 
purified by column chromatography (pentane/acetone: 3/1), yielding 15 g of an amber oil 
(90%). Rf 0.31 (pentane/acetone: 3/1); 1H NMR (300.13 MHz, CDCl3)  0.87 (9H, t, J = 7.2 
Hz), 0.93-0.98 (6H, m), 1.19 (6H, t, J = 7.0 Hz), 1.26-1.35 (6H, m), 1.42-1.52 (6H, m), 3.88-
3.95 (4H, m), 4.39-4.41 (2H, m), 5.06 (2H, s), 6.53 (1H, dt, J = 62.7 and 5.5 Hz), 7.33-7.35 
(5H, m), 7.54 (1H, d, J = 7.7 Hz), 7.62 (1H, app t, J = 7.6 Hz), 7.71 (1H, app t, J = 7.5 Hz), 
8.04 (1H, d, J = 8.0 Hz); 13C NMR (75.47 MHz, CDCl3)  10.8 (-CH2), 13.6 (-CH3), 27.3 
(-CH2), 28.8 (-CH2), 55.2 (-NCH2, 3JPC = 13.8 Hz), 61.1 (-OCH2, 3JPC = 5.5 Hz), 80.2 
(-OCH2), 123.8 (=CH), 126.6 (=C), 128.5 (=CH), 128.9 (=CH), 129.6 (=CH), 131.1 (=CH), 
132.6 (=CH), 136.2 (=C), 136.4 (=C-P, 1JPC = 247.6 Hz), 149.8 (=C), 152.1 (=CH, 2JPC = 1.7 
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Hz); 31P NMR (121.50 MHz, CDCl3)  21.4; Exact mass (ESI-MS): calculated for 
C32H51N2O8PSSn ([M,120Sn]+Na+) 797.20235; found 797.19986. 
Diethyl 3-[N-benzyloxy,N-(2-nitrobenzenesulfonyl)amino]-1-(4-nitrophenyl)-
propenylphosphonate (10f). (2-furyl)3P (12 mg, 0.051 mmol) was added to a solution of 
Pd2dba3.CHCl3 (6 mg, 0.0065 mmol) in anhydrous NMP (2 mL) and the mixture was stirred 
for 1 h at rt. A solution of 6 (216 mg, 0.280 mmol) and 1-iodo-4-nitrobenzene (62 mg, 0.249 
mmol) in anhydrous NMP (5 mL) was added dropwise over a 15 min-period. After the 
addition of anhydrous CuI (46 mg, 0.280 mmol), the reaction mixture was stirred overnight 
protected from light. EtOAc (100 mL) was added and the organic layer was washed 3 times 
with 5% NH4OH (10 mL) and 3 times with saturated aqueous NaCl (10 mL). The organic 
layer was dried over anhydrous MgSO4, filtered and the solvents were removed under reduced 
pressure. The residual oil was purified by column chromatography (pentane/CH2Cl2/acetone: 
3/1/1) yielding 98 mg of a pale yellow oil (58%). Rf 0.48 (pentane/acetone: 1/1); 1H NMR 
(300.13 MHz, CDCl3)  1.16 (6H, t, J = 7.0 Hz), 3.92 (2H, ddq, J = 10.4, 8.4 and 7.1 Hz), 
4.01 (2H, ddq, J = 10.3, 8.1 and 7.0 Hz), 4.47 (2H, dd, J = 5.7 and 3.3 Hz), 5.01 (2H, s), 6.05 
(1H, dt, J = 46.0 and 6.0 Hz), 7.16-7.33 (7H, m), 7.61 (1H, dd, J = 7.7 and 1.4 Hz), 7.72 (1H, 
app dt, J = 7.7 and 1.4 Hz), 7.79 (1H, app dt, J = 7.7 and 1.5 Hz), 8.1 (1H, dd, J = 8.0 and 1.4 
Hz), 8.14 (2H, d, J = 8.4 Hz); 13C NMR (75.47 MHz, CDCl3)  16.1 (-CH3, 3JPC = 6.6 Hz), 
53.1 (-NCH2, 3JPC = 5.4 Hz), 62.3 (-OCH2, 3JPC = 6.0 Hz), 79.6 (-OCH2), 123.4 (=CH), 123.9 
(=CH), 126.0 (=C), 128.5 (=CH), 128.8 (=CH, 3JPC = 1.1 Hz), 129.0 (=CH), 130.1 (=CH), 
131.3 (=CH), 132.6 (=C-P, 1JPC = 176.2 Hz), 132.7 (=CH), 134.8 (=C) 135.2 (=CH), 145.3 
(=C, 2JPC = 10.2 Hz), 145.8 (=CH, 2JPC = 8.2 Hz), 147.3 (=C, 5JPC = 1.1 Hz), 149.9 (=C); 31P 
NMR (121.50 MHz, CDCl3)  13.2; Exact mass (ESI-MS): calculated for C26H28N3O10PS 
([M]+H+) 606.13113; found 606.13014. 
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Diethyl (E)-3-[N-acetyl,N-(benzyloxy)amino)-1-(tributylstannyl)-propenylphosphonate 
(11). To a stirred solution of 6 (15 g, 19.4 mmol) and anhydrous K2CO3 (10.8 g, 77.8 mmol) 
in MeCN (500 mL) containing dry DMSO (10 mL) was added PhSH (6 mL, 58.3 mmol) over 
a 30 min-period at 70 °C. After stirring for 1 h at the same temperature, Ac2O (18.3 mL, 195 
mmol) was added and the reaction was stirred for another 30 min. After cooling to room 
temperature, the reaction was quenched with saturated NaHCO3. The aqueous layer was 
extracted with CH2Cl2; the combined organic fractions were dried over anhydrous MgSO4, 
filtered and concentrated under vacuum. The residual oil was purified via column 
chromatography (pentane/CH2Cl2/acetone: 2/1/1) yielding 11 g of a yellow oil (90%). Rf 0.35 
(pentane/CH2Cl2/acetone: 3/1/1); 1H NMR (300.13 MHz, CDCl3)  0.85 (9H, t, J = 7.3 Hz), 
0.94-0.99 (6H, m), 1.22-1.34 (12H, m), 1.41-1.51 (6H, m), 2.07 (3H, s), 3.94-4.11 (4H, m), 
4.86 (2H, s), 4.89-4.99 (2H, m), 6.48 (1H, dt, J = 63.5 and 5.9 Hz); 13C NMR (75.47 MHz, 
CDCl3)  10.6 (-CH2), 13.6 (-CH3), 16.4 (-CH3, 3JPC = 6.6 Hz), 20.5 (-CH3), 27.3 (-CH2), 
28.7 (-CH2), 57.1 (-NCH2), 61.1 (-OCH2, 2JPC = 5.5 Hz), 76.0 (-OCH2), 128.6 (=CH), 128.9 
(=CH), 129.5 (=CH), 134.4 (=C), 135.1 (=C-P, 1JPC = 133.4 Hz), 155.0 (=CH), 172.1 
(N-C=O); Exact mass (ESI-MS): calculated for C28H50NO5PSn ([M,120Sn]+H+) 632.25269; 
found 632.25282.  
Diethyl (Z)-3-[N-acetyl,N-(benzyloxy)amino]-1-(4-trifluoromethylphenyl)-
propenylphosphonate (12a). (2-furyl)3P (27.2 mg, 0.116 mmol) was added to a solution of 
Pd2dba3.CHCl3 (13.6 mg, 0.0149 mmol) in anhydrous NMP (3 mL) and the mixture was 
stirred at rt for 1 h. A solution of 11 (400 mg, 0.634 mmol) and 1-iodo-4-
trifluoromethylbenzene (154 mg, 0.566 mmol) in anhydrous NMP (5 mL) was added over a 
period of 15 min. After the addition of anhydrous CuI (104 mg, 0.634 mmol) the reaction 
mixture was stirred overnight protected from light. EtOAc (200 mL) was added and the 
organic layer was washed 3 times with 5% NH4OH (24 mL) and 3 times with saturated 
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aqueous NaCl (24 mL). The organic layer was dried over anhydrous MgSO4, filtered and 
concentrated under vacuum. The residual oil was purified by column chromatography 
(pentane/acetone: 55/45) to yield 228 mg of a pale yellow oil (88%). Rf 0.43 (pentane/acetone: 
3/2); 1H NMR (300.13 MHz, CDCl3)  1.24 (6H, t, J = 7.1 Hz), 2.09 (3H, s), 3.98-4.18 (4H, 
m), 4.91 (2H, s), 5.06 (2H, dd, J = 5.8 and 2.9 Hz), 6.46 (1H, dt, J = 47.1 and 6.4 Hz), 7.35-
7.41 (5H, m), 7.43 (2H, d, J = 8.1 Hz), 7.56 (2H, d, J = 8.4 Hz); 13C NMR (75.47 MHz, 
CDCl3)  16.2 (-CH3, 3JPC = 6.6 Hz), 20.5 (-CH3), 45.3 (-NCH2), 62.2 (-OCH2, 2JPC = 5.5 
Hz), 76.4 (-OCH2), 123.9 (-CF3, q, 1JFC = 286.5 Hz), 128.5 (=CH, q, 3JFC = 3.4 Hz), 128.7 
(=CH), 129.0 (=CH), 129.4 (=CH), 129.8 (=C, dq, 2JFC = 32.0 Hz , 5JPC = 1.1 Hz), 132.9 (=C-
P, 1JPC = 196.5 Hz), 134.0 (=C), 142.5 (=C, 2JPC = 11.5 Hz), 147.4 (=CH, 2JPC = 10.5 Hz), 
172.6 (N-C=O); 31P NMR (121.50 MHz, CDCl3)  14.3; ESMS m/z 486 ([M]+H+). 
Diethyl 3-[N-acetyl,N-(hydroxy)amino]-1-(4-trifluoromethylphenyl)-
propylphosphonate (13a). To a solution of 12a (266 mg, 0.547 mmol) in dry THF (8.5 mL) 
was added anhydrous Na2CO3 (174 mg, 1.64 mmol) and Pd/C (133 mg, 10%). The suspension 
was hydrogenated at room temperature and at a slightly positive atmospheric pressure for 4 h. 
The catalyst was removed by filtration through celite, which was washed with portions of 
CH2Cl2. The filtrate was evaporated under reduced pressure and the residual oil was purified 
by column chromatography (CH2Cl2/MeOH: 94/6) yielding a colorless oil (85%). Rf 0.29 
(CH2Cl2/acetone: 1/1); 1H NMR (300.13 MHz, CDCl3)  1.19 (3H, t, J = 7.1 Hz), 1.23 (3H, t, 
J = 7.1 Hz), 2.12 (3H, s), 2.14-2.61 (2H, m), 3.18 (1H, dt, J = 23.1 and 6.1 Hz), 3.36 (1H, dt, 
J = 14.2 and 4.8 Hz), 3.44-4.02 (5H, m), 7.40 (2H, d, J = 7.7 Hz), 7.57 (2H, d, J = 7.9 Hz), 
9.44 (1H, br s); 13C NMR (75.47 MHz, CDCl3)  16.2 (-CH3, 3JPC = 6.0 Hz), 20.5 (-CH3), 
27.9 (-CH2, 2JPC = 2.2 Hz), 41.0 (P-CH, minor, 1JPC = 139.9 Hz), 41.8 (P-CH, major, 1JPC = 
137.2 Hz), 46.2 (-NCH2, major, 3JPC = 10.4 Hz), 46.5 (-NCH2, minor, 3JPC = 15.9 Hz), 62.8 
(-OCH2, 2JPC = 7.2 Hz), 63.2 (-OCH2, 2JPC = 7.7 Hz), 121.3 (-CF3, q, 1JFC = 273.2 Hz), 125.5 
 18
(=CH), 129.5 (=CH, 3JPC = 6.6 Hz), 129.6 (=C, dq, 2JFC = 33.2 Hz, 5JPC = 2.2 Hz), 140.8 (=C, 
2JPC = 7.7 Hz), 172.5 (N-C=O); 31P NMR (121.50 MHz, CDCl3)  26.6, 28.7 (minor, major); 
Exact mass (ESI-MS): calculated for C16H23F3NO5P ([M]+H+) 398.13443; found 398.13310. 
Diethyl 3-[N-acetyl,N-(benzyloxy)amino]-1-(thien-2-yl)-propylphosphonate (14g). The 
title compound was prepared according to the procedure described for 13a, but using 1.2 eq of 
10% Pd/C, resulting in a thick grey oil (50%). Rf 0.44 (pentane/acetone: 1/1); 1H NMR 
(300.13 MHz, CDCl3) 1.15 (3H, t, J = 7.0 Hz), 1.26 (3H, t, J = 7.2 Hz), 2.03 (3H, s), 2.12-
2.26 (1H, m), 2.40-2.54 (1H, m), 3.39 (1H, ddd, J = 22.9, 11.3 and 3.7 Hz), 3.52 (1H, ddd, J = 
14.3, 8.5 and 4.9 Hz), 3.66-3.73 (1H, m), 3.77-4.12 (4H, m), 4.71 (1H, br s), 4.81 (1H, br s), 
6.95-7.00 (2H, m), 7.20-7.23 (1H, m), 7.29-7.27 (5H, m); 13C NMR (75.47 MHz, CDCl3)  
16.3 (-CH3, 3JPC = 6.0 Hz), 16.4 (-CH3, 3JPC = 6.0 Hz), 20.5 (-CH3), 28.5 (-CH2, 2JPC = 1.7 
Hz), 33.6 (P-CH, minor, 1JPC = 139.8 Hz), 37.5 (P-CH, major, 1JPC = 143.8 Hz), 43.7 
(-NCH2), 61.5 (-OCH2, 2JPC = 6.6 Hz, major), 61.6 (-OCH2, 2JPC = 6.6 Hz, minor), 62.3 
(-OCH2, 2JPC = 7.1 Hz, major), 62.9 (-OCH2, 2JPC = 7.1 Hz, minor), 76.2 (-OCH2, major), 
76.4 (-OCH2, minor), 124.8 (=CH, 5JPC = 2.8 Hz), 126.9 (=CH,3JPC = 3.3 Hz), 127.0 (=CH, 
4JPC = 8.2 Hz), 128.7 (=CH), 128.9 (=CH), 129.2 (=CH), 134.4 (=CH), 137.4 (=C, 2JPC = 8.8 
Hz), 171.2 (N-C=O); 31P NMR (121.50 MHz, CDCl3)  25.9; Exact mass (ESI-MS): 
calculated for C20H28NO5PS ([M]+H+) 426.15041; found 426.14882. 
Diethyl 3-[N-acetyl,N-(hydroxy)amino]-1-(thien-2-yl)-propylphosphonate (13g). A 1 M 
solution of BCl3 in hexanes (1.6 mL, 1.60 mmol) was added dropwise to a stirred solution of 
14g (169 mg, 0.397 mmol) in dry CH2Cl2 (7 mL) at –50 °C. After stirring for 30 min at –50 
°C, the reaction was quenched with saturated NaHCO3 (10 mL) and the reaction mixture was 
allowed to warm to rt. The aqueous layer was extracted with CH2Cl2, dried over anhydrous 
MgSO4, filtered and the solvents were removed under reduced pressure. The residual oil was 
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purified by column chromatography (CH2Cl2/MeOH: 94/6) to give the title compound as a 
thick grey oil (69%). Rf 0.19 (CH2Cl2/Acetone: 1/1); 1H NMR (300.13 MHz, CDCl3)  1.15-
1.34 (6H, m), 2.14 (3H, s) 2.17-2.60 (2H, m), 3.46 (1H, dt, J = 22.8 and 5.3 Hz), 3.61-4.12 
(6H, m), 6.95-7.02 (2H, m), 7.20-7.22 (1H, m), 9.42 (1H, br s); 13C NMR (75.47 MHz, 
CDCl3)  16.3 (-CH3, 3JPC = 5.4 Hz), 20.6 (-CH3), 29.6 (-CH2, major, 2JPC = 3.3 Hz), 29.7 
(-CH2, minor, 2JPC = 3.3 Hz), 37.1 (P-CH, 1JPC =142.2 Hz), 46.3 (-NCH2), 62.9 (-OCH2, 2JPC 
= 6.0 Hz), 63.4 (-OCH2, 2JPC = 7.7 Hz), 124.9 (=CH), 127.0 (=CH, 4JPC = 7.5 Hz), 127.2 
(=CH), 138.1 (=C), 172.5 (N-C=O); 31P NMR (121.50 MHz, CDCl3)  25.6, 28.0 
(minor,major); Exact mass (ESI-MS): calculated for C13H22NO5PS ([M]+Na+) 358.08540; 
found 358.08417. 
3-[N-acetyl,N-(hydroxy)amino]-1-(4-trifluoromethylphenyl)-propylphosphonic acid 
(3a). To a solution of 13a (150 mg, 0.377 mmol) in dry MeCN (3.8 mL) was added dropwise 
TMSBr (497 L, 3.77 mmol) at rt and the mixture was stirred for 2 days at rt. The solvents 
were removed under reduced pressure and the remaining traces of TMSBr were removed 
under high vacuum (0.05 mbar). The residual oil was dissolved in 2 mL of distilled water and 
lyophilized. The resulting solid was purified via reversed phase HPLC using a 5 mM 
NH4OAc solution for 5 min followed by a gradient elution of 5 mM NH4OAc solution to 
MeCN in 15 min. The appropriate fractions were lyophilized to give 23 mg of the phosphonic 
acid as a colorless hygroscopic solid (23%). 1H NMR (300.13 MHz, D2O)  1.75 (3H, minor, 
s), 2.01 (3H, major, s), 2.25-2.61 (2H, m), 3.00-3.18 (1H, m), 3.43-3.67 (2H, m), 7.46-7.64 
(2H, m), 7.66-7.84 (2H, m); 19.3 (-CH3), 26.7 (-CH3, major), 26.9 (-CH3, minor), 43.5 (P-CH, 
minor, 1JPC = 131.1 Hz), 44.2(P-CH, major, 1JPC = 130.0 Hz), 46.3 (-NCH2, 3JPC = 17.6 Hz), 
121.9 (-CF3, q, 1JFC = 271.1 Hz) 125.3 (=CH, major), 125.6 (=CH, minor), 128.1 (=C, dq, 
2JFC = 31.8 Hz, 5JPC = 3.3 Hz), 129.6 (=CH, 3JPC = 5.5 Hz), 142.8 (=C, minor), 143.0 (=C, 
major, 2JPC = 7.2 Hz), 173.7 (N-C=O, major)? 173.8 (N-C=O, minor); 31P NMR (121.50 
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MHz, D2O)  21.5; Exact mass (ESI-MS): calculated for C12H15F3NO5P ([M]-H+) 340.05617; 
found 340.05641. 
Bisammonium 3-[N-acetyl,N-(hydroxy)amino]-1-(4-cyanophenyl)-propylphosphonate 
(4b). To a solution of 13b (130 mg, 0.367 mmol) in dry MeCN (3.7 mL) was added dropwise 
TMSBr (484 L, 3.67 mmol) at rt and the mixture was stirred for 24 hours at rt. The solvents 
were removed under reduced pressure and the traces of TMSBr were removed under high 
vacuum (0.05 mbar). The residual oil was dissolved in 2 mL of Type I water and the pH of the 
mixture was adjusted to 8-9 with a 5% NH4OH solution. The solution was lyophilized and the 
residual solid was purified by Whatman CF11 cellulose column chromatography 
(MeCN/NH4OH (aq, 1 M): 3/1). The fractions were assayed using cellulose TLC and the spots 
were visualized under UV-light (365 nm) after dipping in a pinacryptol yellow solution (0.1% 
in H2O) and drying the plate under a stream of hot air.27 The appropriate fractions were 
lyophilized, yielding 79 mg of a pale amber hygroscopic solid (66%). Rf 0.33 (cellulose TLC, 
MeCN/NH4OH(aq, 1M)) : 3/1); 1H NMR (300.13 MHz, D2O)  1.64 (3H, minor, s), 1.90 (3H, 
major, s), 2.12-2.49 (2H, m), 2.94 (1H, ddd, J = 22.0, 12.1 and 2.8 Hz), 3.35 (1H, app dt, J = 
14.4 and 5.7 Hz), 3.50 (1H, ddd, J = 14.4, 8.4 and 6.1 Hz), 7.39 (2H, dd, J = 8.3 and 1.7 Hz), 
7.65 (2H, d, J = 8.2 Hz); 13C NMR (75.47 MHz, D2O)  19.1 (-CH3, major), 19.3 (-CH3, 
minor), 26.5 (-CH2, major), 26.7 (-CH2, minor), 44.0 (P-CH, minor, 1JPC = 126.8 Hz), 44.5 
(P-CH, major, 1JPC = 127.4 Hz), 46.1 (-NCH2, major, 3JPC = 17.1 Hz), 49.6 (-NCH2, minor, 
3JPC = 17.0 Hz), 108.8 (=C, 5JPC = 3.3 Hz), 120.0 (-CN), 129.8 (=CH, 3JPC = 6.1 Hz), 132.3 
(=CH, major, 4JPC = 2.2 Hz), 132.6 (=CH, minor, 4JPC = 1.6 Hz), 145.1 (=C, 2JPC = 7.2 Hz), 
173.6 (N-C=O); 31P NMR (121.50 MHz, D2O)  20.0, 20.5 (minor, major) Exact mass (ESI-
MS): calculated for C12H21N4O5P ([M]-2(NH4+)+H+) 297.06403; found 297.06454. 
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Diethyl (E)-3-[N-(benzyloxy),N-formylamino)-1-(tributylstannyl)-
propenylphosphonate (15). To a stirred solution of 6 (3.04 g, 3.93 mmol) and anhydrous 
K2CO3 (728 mg, 5.23 mmol) in MeCN (100 mL), containing dry DMSO (2 mL), was added 
PhSH (404 L, 3.93 mmol) over a 30 min-period at 70 °C and the reaction mixture was 
stirred overnight at the same temperature. The reaction mixture was then cooled to 0 °C and 
the formylating solution [prepared in a separate flask by adding HCOOH (99%, 163 L, 4.32 
mmol) dropwise to a solution of 1,1’-carbonyldiimidazole (702 mg, 4.32 mmol) in dry 
CH2Cl2 (6.4 mL) at 0 °C for and stirring for 1 h] was added dropwise at 0 °C. The reaction 
mixture was stirred for 1 h at 0 °C. The reaction was quenched with saturated NaHCO3 and 
the aqueous layer was extracted with CH2Cl2. The combined organic fractions were dried over 
anhydrous MgSO4, filtered and the solvents were removed under reduced pressure. The 
residual oil was purified by column chromatography (pentane/CH2Cl2/acetone: 4/1/1) to give 
1.42 g of the title compound as a yellow oil (59%). Rf 0.43 (hexane/acetone: 7/3); 1H NMR 
(300.13 MHz, CDCl3)  0.86 (6H, minor, t, J = 7.3 Hz), 0.87 (6H, major, t, J = 7.2 Hz), 0.95-
1.00 (6H, m), 1.22-1.34 (12H, m), 1.41-1.57 (6H, m), 3.95-4.06 (6H, m), 4.71 (2H, minor, s), 
4.87 (4H, major, m), 6.34-6.55 (1H, minor, m), 6.71 (1H, major, dt, J = 64.2 and 5.8 Hz), 
7.27-7.35 (5H, m), 8.16 (1H, br s); 13C NMR (75.47 MHz, CDCl3)  10.6 (-CH2, minor), 10.7 
(-CH2, major), 13.6 (-CH3, minor), 13.6 (-CH3, major), 16.3 (-CH3, minor, 3JPC = 6.6 Hz); 
16.4 (-CH3, major, 3JPC =7.2 Hz), 27.2 (-CH2, minor) 27.3 (-CH2, major), 28.7 (-CH2 minor), 
28.8 (-CH2, major), 45.7 (-NCH2, major, 3JPC = 15.4 Hz), 54.0 (-NCH2, minor, 3JPC = 13.2 
Hz), 61.0 (-OCH2, minor, 2JPC = 5.5 Hz), 61.1 (-OCH2, major, 2JPC = 5.5 Hz), 76.1 (-OCH2, 
minor), 77.0 (-OCH2, major), 127.8 (=CH, minor), 128.2 (=CH, minor), 128.3 (=CH, minor), 
128.6 (=CH, major), 129.0 (=CH, major), 129.5 (=CH, major), 133.9 (=C-P, 1JPC = 133.4 Hz), 
137.7 (=C), 153.6 (=CH, minor), 157.8 (=CH, major), 162.6 (N-C=O); 31P NMR (121.50 
 22
MHz, CDCl3)  21.7, 22.4 (minor, major); Exact mass (ESI-MS): calculated for 
C27H48NO5PSn ([M,120Sn]+H+) 618.23704; found 618.23725. 
DOXP reductoisomerase inhibition assay. The assay was performed in a reaction mixture 
containing 100 mM Tris HCl (pH 7.5), 0.2 % bovine serum albumin, 1 mM MnCl2, 1 mM 
DOXP, 0.3 mM NADPH, and 1 µg/ml recombinant DOXP reductoisomerase of E. coli. The 
mixture without substrate was pre-incubated with a serial dilution of the test compounds on a 
96 well plate at 30°C for 5 min. The compounds had been dissolved in 100 mM Tris HCl (pH 
7.5) and pre-diluted to the 10fold final concentrations on a separate plate. The reaction was 
started by the addition of DOXP. The decrease of absorption was monitored at 340 nm.  
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